Inhibition of breast cancer cell adhesion and bone metastasis by the extracellular adherence protein of Staphylococcus aureus

Biochemical and Biophysical Research Communications

Volumn 357, Issue 1, 2007, Pages 282-288

  Schneider, Darius ^b   Liaw, Lucy ^c   Daniel, Carolin ^d   Athanasopoulos, Athanasios N ^b   Herrmann, Mathias ^e   Preissner, Klaus T ^f   Nawroth, Peter P ^b   Chavakis, Triantafyllos ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Maine Medical Center Research Institute   (United States)

^d GOETHE UNIVERSITY   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Adhesion; Bone metastasis; Breast cancer; Integrin; Osteopontin

Indexed keywords

MATRIX METALLOPROTEINASE; OSTEOPONTIN;

ANIMAL CELL; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; STAPHYLOCOCCUS AUREUS;

BACTERIAL PROTEINS; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA; CELL ADHESION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RNA-BINDING PROTEINS;

STAPHYLOCOCCUS AUREUS;

EID: 34247118649     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.03.143     Document Type: Article

References (32)

1. Kamby C. The pattern of metastases in human breast cancer: methodological aspects and influence of prognostic factors. Cancer Treat. Rev. 17 (1990) 37-61
2. Plunkett T.A., Smith P., and Rubens R.D. Risk of complications from bone metastases in breast cancer. implications for management. Eur. J. Cancer 36 (2000) 476-482
3. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verastegui E., and Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50-56
4. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin. Exp. Metastasis 20 (2003) 203-213
5. Felding-Habermann B., O'Toole T.E., Smith J.W., Fransvea E., Ruggeri Z.M., Ginsberg M.H., Hughes P.E., Pampori N., Shattil S.J., Saven A., and Mueller B.M. Integrin activation controls metastasis in human breast cancer. Proc. Natl. Acad. Sci. USA 98 (2001) 1853-1858
6. Felding-Habermann B., Fransvea E., O'Toole T.E., Manzuk L., Faha B., and Hensler M. Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin. Exp. Metastasis 19 (2002) 427-436
7. van der P., Vloedgraven H., Papapoulos S., Lowick C., Grzesik W., Kerr J., and Robey P.G. Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components. Lab. Invest. 77 (1997) 665-675
8. Takayama S., Ishii S., Ikeda T., Masamura S., Doi M., and Kitajima M. The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression. Anticancer Res. 25 (2005) 79-83
9. Teitelbaum S.L. Osteoclasts and integrins. Ann. NY Acad. Sci. 1068 (2006) 95-99
10. Standal T., Borset M., and Sundan A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp. Oncol. 26 (2004) 179-184
11. Chellaiah M.A., Kizer N., Biswas R., Alvarez U., Strauss-Schoenberger J., Rifas L., Rittling S.R., Denhardt D.T., and Hruska K.A. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol. Biol. Cell 14 (2003) 173-189
12. Nemoto H., Rittling S.R., Yoshitake H., Furuya K., Amagasa T., Tsuji K., Nifuji A., Denhardt D.T., and Noda M. Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J. Bone Miner. Res. 16 (2001) 652-659
13. Harms J.F., et al. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin. Exp. Metastasis 21 (2004) 119-128
14. Rangaswami H., Bulbule A., and Kundu G.C. Osteopontin: role in cell signaling and cancer progression. Trends Cell. Biol. 16 (2006) 79-87
15. Bautista D.S., Xuan J.W., Hota C., Chambers A.F., and Harris J.F. Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J. Biol. Chem. 269 (1994) 23280-23285
16. Yokosaki Y., Matsuura N., Sasaki T., Murakami I., Schneider H., Higashiyama S., Saitoh Y., Yamakido M., Taooka Y., and Sheppard D. The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J. Biol. Chem. 274 (1999) 36328-36334
17. Agnihotri R., Crawford H.C., Haro H., Matrisian L.M., Havrda M.C., and Liaw L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J. Biol. Chem. 276 (2001) 28261-28267
18. Gao Y.A., Agnihotri R., Vary C.P., and Liaw L. Expression and characterization of recombinant osteopontin peptides representing matrix metalloproteinase proteolytic fragments. Matrix Biol. 23 (2004) 457-466
19. Bayless K.J., and Davis G.E. Identification of dual alpha 4beta1 integrin binding sites within a 38 amino acid domain in the N-terminal thrombin fragment of human osteopontin. J. Biol. Chem. 276 (2001) 13483-13489
20. Chavakis T., Wiechmann K., Preissner K.T., and Herrmann M. Staphylococcus aureus interactions with the endothelium: the role of bacterial "secretable expanded repertoire adhesive molecules" (SERAM) in disturbing host defense systems. Thromb. Haemost. 94 (2005) 278-285
21. McGavin M.H., Krajewska-Pietrasik D., Ryden C., and Hook M. Identification of a Staphylococcus aureus extracellular matrix-binding protein with broad specificity. Infect. Immun. 61 (1993) 2479-2485
22. Jonsson K., McDevitt D., McGavin M.H., Patti J.M., and Hook M. Staphylococcus aureus expresses a major histocompatibility complex class II analog. J. Biol. Chem. 270 (1995) 21457-21460
23. Chavakis T., Hussain M., Kanse S.M., Peters G., Bretzel R.G., Flock J.I., Herrmann M., and Preissner K.T. Staphylococcus aureus extracellular adherence protein serves as anti-inflammatory factor by inhibiting the recruitment of host leukocytes. Nat. Med. 8 (2002) 687-693
24. Athanasopoulos A.N., Economopoulou M., Orlova V.V., Sobke A., Schneider D., Weber H., Augustin H.G., Eming S.A., Schubert U., Linn T., Nawroth P.P., Hussain M., Hammes H.P., Herrmann M., Preissner K.T., and Chavakis T. The extracellular adherence protein (Eap) of Staphylococcus aureus inhibits wound healing by interfering with host defense and repair mechanisms. Blood 107 (2005) 2720-2727
25. Chavakis T., Kanse S.M., Lupu F., Hammes H.P., Muller-Esterl W., Pixley R.A., Colman R.W., and Preissner K.T. Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions. Blood 96 (2000) 514-522
26. Tester A.M., Sharp J.A., Dhanesuan N., Waltham M., and Thompson E.W. Correlation between extent of osteolytic damage and metastatic burden of human breast cancer metastasis in nude mice: real-time PCR quantitation. Clin. Exp. Metastasis 19 (2002) 377-383
27. Kiessling F., Greschus S., Lichy M.P., Bock M., Fink C., Vosseler S., Moll J., Mueller M.M., Fusenig N.E., Traupe H., and Semmler W. Volumetric computed tomography (VCT): a new technology for noninvasive, high-resolution monitoring of tumor angiogenesis. Nat. Med. 10 (2004) 1133-1138
28. Das R., Mahabeleshwar G.H., and Kundu G.C. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J. Biol. Chem. 279 (2004) 11051-11064
29. Furger K.A., Menon R.K., Tuckl A.B., Bramwelll V.H., and Chambers A.F. The functional and clinical roles of osteopontin in cancer and metastasis. Curr. Mol. Med. 1 (2001) 621-632
30. Pecheur I., Peyruchaud O., Serre C.M., Guglielmi J., Voland C., Bourre F., Margue C., Cohen-Solal M., Buffet A., Kieffer N., and Clezardin P. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J. 16 (2002) 1266-1268
31. Rudland P.S., Platt-Higgins A., El-Tanani M., De Silva Rudland S., Barraclough R., Winstanley J.H., Howitt R., and West C.R. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 62 (2002) 3417-3427
32. Wai P.Y., and Kuo P.C. The role of osteopontin in tumor metastasis. J. Surg. Res. 121 (2004) 228-241